Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada

被引:136
作者
Gitt, Anselm K. [1 ]
Drexel, Heinz [2 ]
Feely, John [3 ]
Ferrieres, Jean [4 ]
Gonzalez-Juanatey, Jose R. [5 ]
Thomsen, Kristian K. [6 ]
Leiter, Lawrence A. [7 ,8 ]
Lundman, Pia [9 ]
da Silva, Pedro M. [10 ]
Pedersen, Terje [11 ]
Wood, David [12 ]
Juenger, Claus [1 ]
Dellea, Pam S. [13 ]
Sazonov, Vasilisa [13 ]
Chazelle, Francois [13 ]
Kastelein, John J. P. [14 ]
机构
[1] Heidelberg Univ, Inst Herzinfarktforsch Ludwigshafen, Herzzentrum Ludwigshafen, D-6900 Heidelberg, Germany
[2] Landeskrankenhaus Feldkirch, Feldkirch, Austria
[3] St James Hosp, Trinity Ctr, Dublin, Ireland
[4] CHU Rangueil, Cardiol Unite 02 B, Unite Prevent Atherosclerose, F-31054 Toulouse, France
[5] Hosp Clin Univ, Serv Cardiol, Santiago De Compostela, Spain
[6] Sydvetjysk Sygehus Esbjerg, Kardiol Klin, Dept Cardiol, Esbjerg, Denmark
[7] Univ Toronto, Toronto, ON M5S 1A1, Canada
[8] St Michaels Hosp, Toronto, ON, Canada
[9] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden
[10] Hosp Santa Maria, Med Serv, Nucl Invest Arterial, Lisbon, Portugal
[11] Ullevaal Univ Hosp, Oslo, Norway
[12] Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Natl Heart & Lung Inst, London, England
[13] Merck & Co Inc, Whitehouse, NJ USA
[14] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
关键词
Cardiovascular disease; cross-sectional study; DYSIS; dyslipidemia; HDL-cholesterol; hydroxymethylglutaryl-CoA reductase inhibitors; LDL-cholesterol; risk; triglycerides; DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; 14; RANDOMIZED-TRIALS; LOW HDL-CHOLESTEROL; LOWERING THERAPY; DYSLIPIDEMIA; PREVALENCE; RISK; EFFICACY; TARGETS;
D O I
10.1177/1741826711400545
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: The prevalence of persistent lipid abnormalities in patients receiving statins in primary and secondary care is needed to formulate recommendations for future treatment. Studies associating cardiovascular risk factors with lipid target goal achievement are lacking. Design: A cross-sectional, observational study that assessed the prevalence of persistent dyslipidemia in patients treated with statins and analyzed predictors of lipid target achievement. Methods: Serum lipid values of 22,063 statin-treated patients were studied in the context of their cardiovascular risk factors, and the potency and composition of their lipid-lowering treatment. European Society of Cardiology recommendations were used to classify patient risk, and to define LDL-cholesterol goal and normal levels for HDL-cholesterol and triglycerides. Results: Overall, 48.2% of patients did not achieve the therapeutic goal for LDL-cholesterol, either as a single lipid anomaly or associated with low HDL-cholesterol, elevated triglycerides, or both. Lack of goal achievement was more prevalent among low-risk patients (55.8%) than high-risk patients (46.8%). Serum LDL-cholesterol levels were lower in high-risk patients. Predictors associated with LDL-cholesterol goal achievement were higher statin dose (odds ratio (OR): 0.35), specialist treatment (OR: 0.74), or combined lipid-lowering therapy (OR: 0.80). Conclusions: Nearly half of statin-treated patients missed their therapeutic LDL-cholesterol goal, highlighting a gap between recommendations and clinical practice. Better achievement of LDL-cholesterol therapeutic goal was found among patients at high cardiovascular risk, those on high statin doses or using combination therapy, and patients managed by specialists. Results suggest that residual dyslipidemia in statin-treated patients at low cardiovascular risk may be reduced by increasing statin dose.
引用
收藏
页码:221 / 230
页数:10
相关论文
共 30 条
[1]
Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events including Physicians' Experience and Evaluation) [J].
Assmann, Gerd ;
Benecke, Heike ;
Neiss, Albrecht ;
Cullen, Paul ;
Schulte, Helmut ;
Bestehorn, Kurt .
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2006, 13 (05) :776-783
[2]
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[3]
New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease [J].
Barter P.J. ;
Puranik R. ;
Rye K.-A. .
Current Cardiology Reports, 2007, 9 (6) :493-498
[4]
Bourgault C, 2005, CAN J CARDIOL, V21, P1187
[5]
Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey [J].
Bruckert, E. ;
Baccara-Dinet, M. ;
Eschwege, E. .
DIABETIC MEDICINE, 2007, 24 (04) :388-391
[6]
Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA) - Gender, ethnicity, and coronary artery calcium [J].
Goff, DC ;
Bertoni, AG ;
Kramer, H ;
Bonds, D ;
Blumenthal, RS ;
Tsai, MY ;
Psaty, BM .
CIRCULATION, 2006, 113 (05) :647-656
[8]
European guidelines on cardiovascular disease prevention in clinical practice: executive summary [J].
Graham, Ian ;
Atar, Dan ;
Borch-Johnsen, Knut ;
Boysen, Gudrun ;
Burell, Gunilla ;
Cifkova, Renata ;
Dallongeville, Jean ;
De Backer, Guy ;
Ebrahim, Shah ;
Gjelsvik, Bjorn ;
Herrman-Lingen, Christoph ;
Hoes, Arno ;
Humphries, Steve ;
Knapton, Mike ;
Perk, Joep ;
Priori, Silvia G. ;
Pyorala, Kalevi ;
Reiner, Zeljko ;
Ruilope, Luis ;
Sans-Menendez, Susana ;
Reimer, Wilma Scholte op ;
Weissberg, Peter ;
Wood, David ;
Yarnell, John ;
Zamorano, Jose Luis .
EUROPEAN HEART JOURNAL, 2007, 28 (19) :2375-2414
[9]
Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes - An unmet challenge for cardiovascular risk reduction [J].
Grant, Richard W. ;
Meigs, James B. .
DIABETES CARE, 2007, 30 (03) :479-484
[10]
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [J].
Grundy, SM ;
Cleeman, JI ;
Merz, CNB ;
Brewer, HB ;
Clark, LT ;
Hunninghake, DB ;
Pasternak, RC ;
Smith, SC ;
Stone, NJ .
CIRCULATION, 2004, 110 (02) :227-239